HIV (Human Immunodeficiency Virus)feSTINCT07516912
Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland
An observational study of HIV (Human Immunodeficiency Virus) and Chlamydia, run by University of Zurich.
Trial summary
The main goal of the observational study is to evaluate participants' satisfaction with free HIV and sexually transmitted infection (STI) testing and counselling offered by the cities of Lucerne and Zurich, Switzerland to young people and people with low incomes. Read more about this study
- Who is it for?
- Ages 16 years and olderHealthy volunteers can take part
- Conditions the study is for
- HIV (Human Immunodeficiency Virus), Chlamydia, Gonorrhea
- How many people
- 1,800 participants
- Where
- No sites listed yet
- Study dates
- 7 Apr 2026to 28 Feb 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: People living in the cities of Lucerne and Zurich, and fullfilling the eligibility criterias of the city programmes either in age or level of income.
Who may be able to join
- taking part in the pilot programmes
- understand the study information
- 16 years of age or older
Who cannot join
- not eligible for the pilot programmes
- not understanding the study information
- less than 16 years old
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: feSTI: Evaluation of Free HIV and STI Testing and Counselling Services for Young and Disadvantaged Populations in Lucerne and Zurich
The main goal of the observational study is to evaluate participants' satisfaction with free HIV and sexually transmitted infection (STI) testing and counselling offered by the cities of Lucerne and Zurich, Switzerland to young people and people with low incomes. Counselling and testing can be accessed without participating in the study arm of the project.
- Conditions
- HIV (Human Immunodeficiency Virus), Chlamydia, Gonorrhea, Syphilis, HCV
- Keywords
- Voluntary counselling and testing, sexually transmitted infections, HIV, implementation of free testing, barriers to care
- Medical subject headings
- Acquired Immunodeficiency Syndrome, Chlamydia Infections, Gonorrhea, Syphilis, Sexually Transmitted Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Participants in municipal free HIV and STI counselling and testing pilot programmes | Participants are people accessing the municipal free HIV and STI counselling and testing pilot programmes. People can be eligible by age or low income. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Participants' satisfaction (study-specific satisfaction scale)
Participants' satisfaction is measured as the proportion of participants who "agree" or "strongly agree" with satisfaction statements in the post-visit questionnaire. 5-point Likert scale (1 = strongly disagree, 5 = strongly agree); higher scores indicate greater agreement, thus higher satisfaction.
Measured: 3 years
Secondary outcomes (14)
Service capacity/utilisation
Number of completed voluntary counselling and testing visits recorded per month across participating sites.
Measured: 3 years
Access timeliness
Median number of days between booking date and appointment date for VCT visits
Measured: 3 years
Workload healthcare providers
Healthcare provider workload assessed via a short survey measuring perceived workload and time burden, assessed using a standardised Likert-type scale (1-5); higher scores indicate greater perceived workload.
Measured: 3 years
Count diagnosed HIV/STI cases
Number of newly diagnosed HIV and STI cases identified through the free voluntary counselling and testing visits across participating sites per reporting period.
Measured: 3 years
Number of treated STI cases
Number of participants who received an STI or HIV diagnosis during the pilot project and subsequently received treatment, defined as antibiotics dispensed at a pharmacy or attendance at a medical appointment at Maihof Praxis Lucerne or Checkpoint Zurich.
Measured: 3 years
Participants' perception of comfort regarding sexual health
Participant-reported comfort regarding sexual health (encompassing physical, emotional, and social wellbeing related to sexuality and relationships), measured on a visual analogue scale from 0 (not comfortable) to 100 (very comfortable). Filled in at clinic while waiting for appointment and again approximately 1 week after the appointment.
Measured: 3 years
Testing behaviour
Testing behaviour assessed via administrative data and self-report. Participants indicate whether this is their first STI/HIV test and, for HIV testing, time since last HIV test. Trends in testing frequency are monitored over the study period.
Measured: 3 years
Changes in sexual health topics familiarity
Participants rate 12 topics on a scale from 1 to 5 (1=never heard of it, 5=very familiar); higher scores indicate greater knowledge. Participants rate their familiarity at the clinic prior to the appointment and approximately 1 week after the appointment. The measure is the change between pre- and post-appointment rating.
Measured: 3 years
Changes in sexual health knowledge
Knowledge assessed using 8 true/false items (total score range: 0-8), administered at the clinic prior to the appointment and again approximately one week post-appointment. Higher scores indicate greater knowledge. The measure is the change in score from pre- to post-appointment.
Measured: 3 years
Changes in self-efficacy/attitudes
Self-efficacy and attitudes assessed using 13 items rated on a 5-point Likert scale (1 = strongly disagree, 5 = strongly agree), administered at the clinic prior to the appointment and again approximately one week post-appointment. Higher scores indicate greater self-efficacy and more positive attitudes. The measure is the change in score from pre- to post-appointment.
Measured: 3 years
Information-seeking behaviour
Information-seeking behaviour is assessed using a multiple-choice question identifying sources of sexual health information (e.g., internet, healthcare provider, peers). Reported descriptively as frequency and distribution of sources selected; administered at the clinic prior to the appointment only.
Measured: 3 years
Proportion of low-income eligible participants
Proportion of participants holding a KulturLegi card (indicating low-income eligibility) among all enrolled participants; reported descriptively.
Measured: 3 years
Reach Among Low-Income Eligible Population
Proportion of KulturLegi card holders enrolled in the study relative to the total number of KulturLegi cards issued in the catchment area during the study period. Assessed by comparing observed reach against a pre-specified target of ≥5% of the eligible low-income population.
Measured: 3 years
Comparative Outcomes by Eligibility Group
STI/HIV positivity rates, re-testing rates, and knowledge scores compared between low-income eligible participants (KulturLegi card holders) and age-eligible participants. Differences between groups are reported descriptively; regression modelling may be applied to explore associations and inform policy decisions.
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2026
- Study start7 Apr 2026 (estimated)
- Primary completion30 Nov 2028 (estimated)
- Study completion28 Feb 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HIV (Human Immunodeficiency Virus)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Prospective
- Enrolment
- 1,800 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Zurich
- Sponsor type
- University, hospital or other
- Collaborators
- Checkpoint Zurich, Checkpoint Lucerne, Test-In Zurich
- Responsible party
- Principal investigator, Andrea Farnham, University of Zurich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07516912
- Sponsor's protocol ID
- feSTI
- Other IDs
- BASEC-Nr: 2025-02292
- Acronym
- feSTI
- Status last verified
- Apr 2026
- First submitted
- 23 Mar 2026
- Last updated
- 8 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared. Access to data is restricted to authorised project personnel. For data sharing partcipant consenst needs to be sought.
Study at a glance
From the registry record, last updated by the sponsor on 8 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- feSTI: Evaluation of Free HIV and STI Testing and Counselling Services for Young and Disadvantaged Populations in Lucerne and Zurich
- ClinicalTrials.gov ID
- NCT07516912
- Acronym / sponsor ID
- feSTI / feSTI
- Conditions
- HIV (Human Immunodeficiency Virus), Chlamydia, Gonorrhea, Syphilis, HCV
- Keywords
- Voluntary counselling and testing, sexually transmitted infections, HIV, implementation of free testing, barriers to care
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 1,800 participants (estimated)
- Lead sponsor
- University of ZurichUniversity, hospital or other
- Collaborators
- Checkpoint Zurich, Checkpoint Lucerne, Test-In Zurich
- Study start
- 7 Apr 2026 (estimated)
- Primary completion
- 30 Nov 2028 (estimated)
- Study completion
- 28 Feb 2029 (estimated)
- First posted
- 8 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main goal of the observational study is to evaluate participants' satisfaction with free HIV and sexually transmitted infection (STI) testing and counselling offered by the cities of Lucerne and Zurich, Switzerland to young people and people with low incomes. Counselling and testing can be accessed without participating in the study arm of the project.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Participants in municipal free HIV and STI counselling and testing pilot programmes | – | –Participants are people accessing the municipal free HIV and STI counselling and testing pilot programmes. People can be eligible by age or low income. |
Who may qualify
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- People living in the cities of Lucerne and Zurich, and fullfilling the eligibility criterias of the city programmes either in age or level of income.
Key inclusion criteria (3 listed)
- taking part in the pilot programmes
- understand the study information
- 16 years of age or older
Key exclusion criteria (3 listed)
- not eligible for the pilot programmes
- not understanding the study information
- less than 16 years old
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Participants' satisfaction (study-specific satisfaction scale)
Time frame: 3 years
Participants' satisfaction is measured as the proportion of participants who "agree" or "strongly agree" with satisfaction statements in the post-visit questionnaire. 5-point Likert scale (1 = strongly disagree, 5 = strongly agree); higher scores indicate greater agreement, thus higher satisfaction.
14 secondary outcomes
Service capacity/utilisation
Time frame: 3 years
Access timeliness
Time frame: 3 years
Workload healthcare providers
Time frame: 3 years
Count diagnosed HIV/STI cases
Time frame: 3 years
Number of treated STI cases
Time frame: 3 years
Participants' perception of comfort regarding sexual health
Time frame: 3 years
Testing behaviour
Time frame: 3 years
Changes in sexual health topics familiarity
Time frame: 3 years
Changes in sexual health knowledge
Time frame: 3 years
Changes in self-efficacy/attitudes
Time frame: 3 years
Information-seeking behaviour
Time frame: 3 years
Proportion of low-income eligible participants
Time frame: 3 years
Reach Among Low-Income Eligible Population
Time frame: 3 years
Comparative Outcomes by Eligibility Group
Time frame: 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Apr 2026.
- Study infromationLink provided by the sponsor.
- Individual participant dataSharing planned: No. Individual participant data will not be shared. Access to data is restricted to authorised project personnel. For data sharing partcipant consenst needs to be sought.
Related trials for HIV (Human Immunodeficiency Virus)
Not yet recruiting
Testing a Multi-Level Approach to Reduce Stigma for Women Living With HIV
HIV (Human Immunodeficiency Virus)
Not yet recruitingPhase 2/3
Reducing Arterial Inflammation Using Eplerenone and Statins in HIV
HIV (Human Immunodeficiency Virus), Cardiovascular Diseases (CVD)
RecruitingPhase 3
A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Recruiting
Feasibility Study Comparing Use of One Or Two Probes for Thermal Ablation Among Screen Positive Women Living With HIV in C1001P-CS2 Kenya
HIV (Human Immunodeficiency Virus), HPV
Not yet recruitingObservational study
C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States
Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of HIV (Human Immunodeficiency Virus) and Chlamydia, run by University of Zurich.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 8 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Andrea C Farnham, PhD (+41 44 634 60 00, testi@ebpi.uzh.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Participants' satisfaction (study-specific satisfaction scale) (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2026; AzTrials last refreshed its copy on 26 Oct 2026.